Phase 2 Oxytocin Plus Self-compassion Training in Borderline Personality Disorder, 80 Patients
Summary
NCT07551882 is a Phase 2 randomized controlled clinical trial evaluating the combined effectiveness of self-compassion training (SCT) and intranasal oxytocin administration versus SCT plus placebo in treating borderline personality disorder (BPD). The study will enroll 80 patients with BPD who will receive a 5-week self-compassion training program along with either intranasal oxytocin or placebo. Clinical and wellness measures will be evaluated as primary outcomes. The trial is registered as Phase 2 with a start date of April 27, 2026.
“A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document registers a Phase 2 clinical trial (NCT07551882) on ClinicalTrials.gov, describing a randomized controlled study evaluating the combined effect of intranasal oxytocin and self-compassion training on borderline personality disorder symptoms. The trial will recruit 80 BPD patients and compare SCT plus oxytocin against SCT plus placebo over 5 weeks.
Healthcare providers and clinical researchers involved in BPD treatment should be aware of this trial's parameters. Self-compassion training is being studied as an intervention targeting self-criticism, shame, and chronic feelings of worthlessness in BPD patients, while intranasal oxytocin is being evaluated for its effects on social cognition, affiliation behaviors, and empathy.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Oxytocin Plus Self-compassion Training in Borderline Personality Disorder
Phase 2 NCT07551882 Kind: PHASE2 Apr 27, 2026
Abstract
Background: Borderline personality disorder (BPD) is a frequentand serious psychiatric disorder characterized by a persistent pattern of instability in relationships, affect and self-image. Although long-term follow-up prospective studies have shown high clinical remission rates, they also point out that usually persist social functioning deficits, comorbidity, isolation, chronic affective clinic and life dissatisfaction. Self-compassion training (SCT) could be an effective strategy targeting self-criticism, shame and chronic feelings of worthlessness, as well as increasing resilience. In addition, the administration of intranasal oxytocin has proven useful in regulating social cognition, affiliation behaviors and enhancing empathy, key symptoms in this population. This combined intervention could be particularly appropriate for BPD patients.
Objective: The objective of this project is to implement and evaluate the effectiveness of a combined intervention, based on SCT and intranasal oxytocin administration, for the treatment of patients with BPD.
Methodology: Controlled and randomized clinical trial. A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD. Clinical and wellness measures will be evalutated as outcomes.
Conditions: Self-compassion Training (SCT) Plus Intranasal Oxytocin, Self-compassion Training (SCT) Plus Intranasal Placebo
Interventions: Intranasal Oxytocin (IN-OXT), Intranasal Placebo, Self-Compassion Training (SCT)
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.